A bioavailable cathepsin S nitrile inhibitor abrogates tumor development

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Cathepsin S is implicated in cancer progression, specifically tumor invasion and neo-angiogenesis.
• Cathepsin S inhibitors may offer clinical utility in cancer treatment.
• A cell-permeable dipeptidyl nitrile inhibitor of cathepsin S was investigated in tumor models.

Purpose of the Study:

• To evaluate the efficacy of a cathepsin S inhibitor in preclinical cancer models.
• To assess the inhibitor's selectivity and its effects on tumor invasion, angiogenesis, and progression.

Main Methods:

• In vitro assays validated cathepsin S selectivity and measured inhibition kinetics.
• Transwell migration assays assessed tumor cell invasion, and HUVEC cells evaluated endothelial tube formation.
• In vivo studies in murine MC38 and human MCF7 tumor models evaluated tumor progression, proliferation (Ki67), and apoptosis (TUNEL).

Main Results:

• The inhibitor selectively targeted cathepsin S over related proteases.
• Significant reduction in tumor cell invasion and endothelial tube formation was observed in vitro.
• In vivo, the inhibitor significantly decreased tumor volume, proliferation, and increased apoptosis in both syngeneic and xenograft models.

Conclusions:

• The study characterized a cathepsin S inhibitor in vitro and in vivo tumor models.
• The findings highlight the compound's potential to elucidate cathepsin S's role in cancer.
• This cathepsin S inhibitor demonstrates therapeutic potential for cancer treatment.